ADMA Biologics, Inc.

NASDAQ:ADMA

Biotechnology

Healthcare
$13.56 +0.42%

+$0.04 today

Market cap
$3.01B
Beta
0.73
P/E (TTM)
12.1
EPS (TTM)
$0.70
52W Low $7.21High $20.46

Volume 3.17M

Average 7.07M

ADMA Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

ADMA Biologics, Inc.NASDAQ: ADMA

Accumulated OCI · Q2 FY2026 · quarter ended Jun 2026

Accumulated OCI remains negative

Q2 FY2026 Accumulated OCI was $0, compared with $0 a year earlier.

Context

  • Accumulated OCI amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
  • Accumulated OCI increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoJun 2025
$0— since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accumulated OCI history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Accumulated OCI vs competitors

How ADMA compares with its peers on the latest reported figures

  • Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
  • Accumulated OCI amounts to 0.0% of total assets for ADMA, versus a peer median of 17.4%.
ADMA Competitors
Accumulated OCI for ADMA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
GRFSGrifols, S.A.Jun 2026€4.42B EUR+7.9%-3.0%22.0%
ADMAADMA Biologics, Inc.Jun 2026$0 USD——0.0%
IVVDInvivyd, Inc.Mar 2026-$37K USD-184.6%—0.0%
ABUSArbutus Biopharma CorporationMar 2026-$48.2M USD-0.1%—17.4%
Peer median (excluding ADMA) —-0.1%-3.0%17.4%

Competitors are the stored peer set for ADMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents51.09M86.52M51.35M103.15M87.63M
Short-term Investments00000
Net Receivables28.58M15.51M27.42M50M158.43M
Inventory124.72M163.28M172.91M170.24M206.47M
Other Current Assets05.1M5.33M8.03M13.99M
Total Current Assets208.73M270.4M257.01M331.41M466.51M
Property, Plant & Equipment (Net)58.2M68.75M63.47M63.34M71.71M
Goodwill3.53M3.53M3.53M3.53M3.53M
Intangible Assets1.73M1.01M499K460K632K
Long-term Investments00000
Tax Assets00084.28M73.26M
Other Non-current Assets4.07M4.77M4.67M5.66M8.6M
Total Non-current Assets67.52M78.06M72.17M157.27M157.73M
Total Assets276.25M348.46M329.18M488.68M624.24M
Account Payables12.43M13.23M15.66M20.22M22.52M
Short-term Debt00002.81M
Tax Payables0003.48M0
Deferred Revenue142.83K143K182K143K0
Other Current Liabilities16.05M1.8M2.37M1.85M6.82M
Total Current Liabilities30.38M39.27M49.81M55.54M69.54M
Long-term Debt94.87M142.83M130.59M72.34M69.33M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)1.98M1.83M1.69M1.55M1.41M
Other Non-current Liabilities397.35K1.85M2.11M1.67M0
Total Non-current Liabilities104.7M157.22M144.17M84.12M77.38M
Total Liabilities135.08M196.49M193.98M139.66M146.92M
Common Stock19.58K22K23K24K24K
Retained Earnings(412.11M)(478.02M)(506.26M)(308.58M)(161.65M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity141.17M151.97M135.21M349.02M477.32M
Total Debt102.92M154.44M141.42M82.12M79.89M
Net Debt51.83M67.92M90.07M(21.03M)(7.75M)

ADMA Biologics, Inc.

NASDAQ:ADMA

Intrinsic Alpha fair value

Locked

Current Price

$13.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.